Cristin-resultat-ID: 1195637
Sist endret: 30. januar 2015, 12:41
Resultat
Vitenskapelig artikkel
2013

High dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008

Bidragsytere:
  • Knut Halvor Bjøro Smeland
  • Cecilie E. Kiserud
  • Grete Fossum Lauritzsen
  • Anne Kirsti Blystad
  • Unn-Merete Fagerli
  • Øystein Fluge
  • mfl.

Tidsskrift

Tidsskrift for Den norske legeforening
ISSN 0029-2001
e-ISSN 0807-7096
NVI-nivå 1

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2013
Publisert online: 2013
Trykket: 2013
Volum: 133
Hefte: 16
Sider: 1704 - 1709
Artikkelnummer: 24005706
Open Access

Beskrivelse Beskrivelse

Tittel

High dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008

Sammendrag

BACKGROUND High-dose therapy with autologous stem cell support (HDT) has been a treatment option for lymphomas in Norway for 25 years. The purpose of the article was to describe the use of the therapy for lymphomas for the country as a whole and by health region, and to reveal the overall survival rate. METHOD All lymphoma patients ≥ 18 years who received HDT in Norway in the period 1987 – 2008 are included. Patients, diagnostics and treatment are identified for each hospital. Data for the population base have been retrieved from Statistics Norway. RESULTS Altogether 726 lymphoma patients received HDT in Norway in the period 1987 – 2008, with an annual average of 0.72 per 100 000 inhabitants. The annual number of treatments increased until 2004 and has since been stable. The average number of treatments per 100 000 inhabitants per year was 0.94 for Northern Norway Health Region, 0.80 for South-Eastern Norway Health Region, 0.58 for Central Norway Health Region and 0.55 for Western Norway Health Region. Early mortality (death within 100 days) was 6  %. Ten-year overall survival was 55  % (95  % CI 51 – 59  %), and Hodgkin’s lymphoma had the best survival of the lymphoma groups (p = 0.01). INTERPRETATION The annual number of HDT increased gradually until 2004. The use of the treatment varied according to the patients’ place of residence at the time of diagnosis, and was most frequently used for patients belonging to Northern Norway Health Region. More than half of the lymphoma patients are alive ten years after the treatment.

Bidragsytere

Knut Halvor Bjøro Smeland

  • Tilknyttet:
    Forfatter
    ved Oslo universitetssykehus HF

Cecilie E. Kiserud

  • Tilknyttet:
    Forfatter
    ved Seksjon for seneffekter ved Oslo universitetssykehus HF

Grete Fossum Lauritzsen

  • Tilknyttet:
    Forfatter

Anne Kirsti Blystad

  • Tilknyttet:
    Forfatter
    ved Avdeling for kreftbehandling ved Oslo universitetssykehus HF

Unn Merete Fagerli

Bidragsyterens navn vises på dette resultatet som Unn-Merete Fagerli
  • Tilknyttet:
    Forfatter
    ved Institutt for klinisk og molekylær medisin ved Norges teknisk-naturvitenskapelige universitet
1 - 5 av 14 | Neste | Siste »